Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Asahi Kasei and Microwave Chemical have initiated a joint project to commercialize a chemical recycling process for polyamide 66 (PA66) using microwave technology, launched in April 2023. This process involves depolymerizing PA66 to directly extract high-yield monomers hexamethylenediamine (HMD) and adipic acid (ADA) with low energy consumption. The project aims to reduce greenhouse gas emissions in PA66 production, leveraging Microwave Chemical's PlaWave™ technology. Laboratory studies confirmed successful depolymerization of PA66, and plans for bench-scale equipment are underway at the Osaka Factory to further validate the process through a small-scale demonstration trial in fiscal 2024. A decision on commercialization will follow by fiscal 2025.